Amniotics (AMNI) investor relations material

Executive summary

• Amniotics develops cell therapies based on neonatal mesenchymal stem cells from amniotic fluid, with a unique patented technology and in-house GMP manufacturing in Lund.

• The company faced significant challenges raising capital, leading to a planned merger with Magle Chemoswed Holding AB, creating "Nya Magle Group".

• PulmoStem™, the lead product, completed a clinical study in 2023 showing positive safety and tolerability data; other pipeline candidates remain in early development.

Financial highlights

• Net sales for H1 2024 were SEK 2.45 million, up from SEK 0 in H1 2023.

• Operating result before depreciation was SEK -10.6 million (improved from SEK -16.6 million year-over-year).

• Total comprehensive income was SEK -7.7 million, an improvement from SEK -18.4 million in H1 2023.

• Cash flow for the period was SEK -8.0 million; cash and cash equivalents at period end were SEK 0.2 million.

• Equity at period end was SEK 8.1 million, with an equity ratio of 47%.

Outlook and guidance

• The merger with Magle Chemoswed is expected to be completed by October 3, 2024, securing the future of Amniotics' assets and staff.

• Short-term capital needs are covered through loan extensions and service agreements with Magle Chemoswed.

• The company aims to advance PulmoStem™ to Phase II/partnership and continue developing its pipeline.